[go: up one dir, main page]

BR0316070A - Composto, composição farmacêutica, uso de um composto e, método para modular mchr - Google Patents

Composto, composição farmacêutica, uso de um composto e, método para modular mchr

Info

Publication number
BR0316070A
BR0316070A BR0316070-0A BR0316070A BR0316070A BR 0316070 A BR0316070 A BR 0316070A BR 0316070 A BR0316070 A BR 0316070A BR 0316070 A BR0316070 A BR 0316070A
Authority
BR
Brazil
Prior art keywords
compound
mchr
modulating
pharmaceutical composition
treating
Prior art date
Application number
BR0316070-0A
Other languages
English (en)
Inventor
Xi Chen
Xiaoqi Chen
Pingchen Fan
Juan Jaen
Leping Li
Jeffrey T Mihalic
Original Assignee
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc filed Critical Tularik Inc
Publication of BR0316070A publication Critical patent/BR0316070A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E, MéTODO PARA MODULAR MCHR". São providos compostos, composições e métodos que são úteis no tratamento e/ou prevenção de uma condição ou distúrbio mediado por um receptor acoplado à proteína-G. Em particular, os compostos da invenção são úteis no tratamento e/ou prevenção de distúrbios de comer, obesidade, distúrbios de ansiedade e distúrbios do humor.
BR0316070-0A 2002-11-06 2003-11-06 Composto, composição farmacêutica, uso de um composto e, método para modular mchr BR0316070A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42445602P 2002-11-06 2002-11-06
PCT/US2003/035543 WO2004043958A1 (en) 2002-11-06 2003-11-06 Fused heterocyclic compounds

Publications (1)

Publication Number Publication Date
BR0316070A true BR0316070A (pt) 2005-09-27

Family

ID=32312811

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316070-0A BR0316070A (pt) 2002-11-06 2003-11-06 Composto, composição farmacêutica, uso de um composto e, método para modular mchr

Country Status (16)

Country Link
US (2) US7253179B2 (pt)
EP (1) EP1562943A1 (pt)
JP (1) JP4547266B2 (pt)
KR (1) KR20050103184A (pt)
CN (2) CN1330651C (pt)
AU (1) AU2003285160B2 (pt)
BR (1) BR0316070A (pt)
CA (1) CA2505372A1 (pt)
EA (1) EA009421B1 (pt)
IS (1) IS7833A (pt)
MX (1) MXPA05004739A (pt)
NO (1) NO20052655L (pt)
NZ (1) NZ540328A (pt)
PL (1) PL376659A1 (pt)
WO (1) WO2004043958A1 (pt)
ZA (1) ZA200503654B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US20070135425A1 (en) * 2001-05-04 2007-06-14 Amgen Inc. Fused heterocyclic compounds
CN1330651C (zh) * 2002-11-06 2007-08-08 安姆根有限公司 稠合杂环化合物
US7727998B2 (en) 2003-02-10 2010-06-01 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
DE102010025663A1 (de) * 2010-06-30 2012-01-05 Karl-Heinz Glüsenkamp Neue beta-Aminoaldehyd-Derivate, Verfahren zu ihrer Herstellung und ihre chemische Verwendung als reaktive Intermediate
JP2013538800A (ja) 2010-08-10 2013-10-17 アッヴィ・インコーポレイテッド 新規ｔｒｐｖ３モジュレーター
US9012651B2 (en) 2011-03-24 2015-04-21 Abbvie Inc. TRPV3 modulators
US8772499B2 (en) 2011-10-24 2014-07-08 Abbvie Inc. TRPV3 modulators
CN106588812B (zh) * 2016-12-07 2019-02-22 烟台大学 一种酰氯制备2，4-二取代噻唑啉类化合物的方法
PL3911631T3 (pl) * 2019-01-14 2025-04-28 Zydus Lifesciences Limited Nowe podstawione pochodne sulfonylomocznika
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US176694A (en) * 1876-04-25 Improvement in screw-cutting die-stocks
US23085A (en) * 1859-03-01 chandler
US199549A (en) * 1878-01-22 Improvement in screw-propellers
JPS5825980B2 (ja) 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
JPS63258474A (ja) 1986-08-15 1988-10-25 セドナ・ファ−マセウチカルズ・ビ−・ブイ カルバゾ−ル、ジベンゾフラン又はジベンゾチオフェン基を含む化合物の水酸基誘導体を調製するための方法
US5049655A (en) 1989-03-22 1991-09-17 The Salk Institute For Biological Studies Melanin-concentrating hormones
JP2906654B2 (ja) 1989-11-28 1999-06-21 東レ株式会社 免疫抑制剤及びその製造方法
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
JP3160941B2 (ja) * 1991-06-17 2001-04-25 東レ株式会社 カルバゾール誘導体および免疫抑制剤
CA2112744A1 (en) 1991-07-05 1993-01-21 Vittorrio Vecchietti Hydroisoquinoline derivatives
FI942499A7 (fi) 1992-09-29 1994-07-27 Toray Industries Indolijohdannainen, menetelmä sen valmistamiseksi ja sen lääkekäyttö
US5272146A (en) 1992-10-02 1993-12-21 The United States Of America As Represented By The United States Department Of Health And Human Services 1,2-dihydroellipticines with activity against CNS specific cancer cell lines
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
US5578725A (en) 1995-01-30 1996-11-26 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US5849708A (en) 1995-06-06 1998-12-15 Joslin Diabetes Center, Inc. Promotion of eating behavior
EP0848060A3 (en) 1996-12-11 2000-02-02 Smithkline Beecham Corporation Novel human 11CB splice variant
JP4110579B2 (ja) 1997-01-16 2008-07-02 東レ株式会社 インドロモルヒナン誘導体および脳障害治療・予防剤
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
EP1042498A4 (en) 1997-12-03 2003-05-07 Smithkline Beecham Corp METHOD FOR SEARCHING FOR AN AGONIST OR ANTAGONIST OF THE HUMAN 11 CB SPLICE VARIANT
EP1085869A4 (en) 1998-06-11 2001-10-04 Merck & Co Inc Spiropiperidine derivatives as melanocortin receptor agonists
CA2342833A1 (en) 1998-09-17 2000-03-23 Incyte Pharmaceuticals, Inc. Human gpcr proteins
GB9822158D0 (en) 1998-10-09 1998-12-02 Nycomed Imaging As Compositions
EP1143000B1 (en) 1998-12-28 2007-02-14 Takeda Pharmaceutical Company Limited Screening method
US6221613B1 (en) 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
WO2000049170A1 (en) 1999-02-18 2000-08-24 Smithkline Beecham Corporation MURINE 11cby RECEPTOR
CN1341123A (zh) 1999-02-19 2002-03-20 武田药品工业株式会社 新型g蛋白偶联型受体蛋白及其dna
AU5260500A (en) 1999-05-19 2000-12-05 Astrazeneca Ab Assays for agonists, agonists and inverse agonists of melanin concentrating hormone (mch) binding to the somatostatin-like receptor (slc-1)
WO2000075166A1 (en) 1999-06-08 2000-12-14 The Regents Of The University Of California Melanin concentrating hormone receptor
EP1200560A4 (en) 1999-07-14 2003-06-11 Merck & Co Inc MELANINE-CONCENTRATING HORMONE RECEPTOR
EP1196570A2 (en) 1999-07-26 2002-04-17 Genentech, Inc. Human polypeptides and methods for the use thereof
EP1196572A1 (en) 1999-07-27 2002-04-17 Smithkline Beecham Plc Axor21, a g-protein coupled receptor
AU7315800A (en) 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Mch antagonists
AU7315700A (en) 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonist
WO2001036479A1 (en) 1999-11-16 2001-05-25 Merck & Co., Inc. G-protein coupled receptor
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
EP1265926A1 (en) 2000-03-15 2002-12-18 Merck & Co., Inc. Melanin concentrating hormone receptor chimeric and fusion proteins
JP2005229804A (ja) 2000-03-24 2005-09-02 Astellas Pharma Inc 新規なメラニンコンセントレーティングホルモン受容体
WO2001087834A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
JP2004504303A (ja) 2000-07-05 2004-02-12 シナプティック・ファーマスーティカル・コーポレーション 選択的メラニン凝集ホルモン−１（ｍｃｈ１）受容体アンタゴニストおよびその使用
AU2001269440A1 (en) 2000-07-05 2002-01-14 Takeda Chemical Industries Ltd. Method for screening mch receptor antagonist/agonist
WO2002002744A2 (en) 2000-07-05 2002-01-10 Synaptic Pharmaceutical Corporation Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
JP2004516239A (ja) * 2000-07-06 2004-06-03 ニューロジェン コーポレイション メラニン凝集ホルモン受容体リガンド
EE200300191A (et) 2000-10-20 2003-10-15 Pfizer Products Inc. Alfa-arüül-etanoolamiinid ja nende kasutamine beeta-3 adrenergiliste retseptorite agonistidena
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
WO2002051809A1 (en) * 2000-12-22 2002-07-04 Schering Corporation Piperidine mch antagonists and their use in the treatment of obesity
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
AU2002247367B2 (en) 2001-03-21 2005-10-27 Pharmacopeia Drug Discovery, Inc. Aryl and biaryl compounds having MCH modulatory activity
ES2340147T3 (es) * 2001-04-12 2010-05-31 Pharmacopeia, Llc Piperidinas de arilo y biarilo usadas como antagonistas de mch.
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
DE60231202D1 (de) 2001-05-04 2009-04-02 Amgen Inc Kondensierte heterozyklische verbindungen
US6953801B2 (en) 2001-05-22 2005-10-11 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
ATE446286T1 (de) * 2001-11-26 2009-11-15 Schering Corp Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems
WO2003060475A2 (en) * 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues
CN1330651C (zh) * 2002-11-06 2007-08-08 安姆根有限公司 稠合杂环化合物

Also Published As

Publication number Publication date
NO20052655D0 (no) 2005-06-02
NZ540328A (en) 2008-02-29
PL376659A1 (pl) 2006-01-09
CN1330651C (zh) 2007-08-08
NO20052655L (no) 2005-07-26
KR20050103184A (ko) 2005-10-27
MXPA05004739A (es) 2005-08-02
JP4547266B2 (ja) 2010-09-22
JP2006508130A (ja) 2006-03-09
CA2505372A1 (en) 2004-05-27
EA009421B1 (ru) 2007-12-28
WO2004043958A1 (en) 2004-05-27
US20080058365A1 (en) 2008-03-06
EP1562943A1 (en) 2005-08-17
US7253179B2 (en) 2007-08-07
CN1735613A (zh) 2006-02-15
EA200500770A1 (ru) 2005-12-29
US20040147538A1 (en) 2004-07-29
CN101134757A (zh) 2008-03-05
ZA200503654B (en) 2006-09-27
IS7833A (is) 2005-05-02
AU2003285160B2 (en) 2009-06-04
AU2003285160A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
BR0009651A (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas
BR9814435A (pt) Novos esteróides antiestrogênicos e composições farmacêuticas associadas
BR9813028A (pt) Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
BR0114410A (pt) Associação de um antagonista de receptor cb1 e de sibutramina, as composições farmacêuticas que os contêm e a respectiva utilização para o tratamento da obesidade
BR0007487A (pt) Difenil-uréias substituìdas com w-carbóxi-arilas como inibidores de raf cinase
BR9913912A (pt) Métodos e composições para tratamento de doenças mediadas por receptor
BR0213207A (pt) remodelagem e glicoconjugação de peptìdeos
BR0313624A (pt) Agonismo do receptor 5ht2a para tratamento da disfunção termo-regulatória
PT800519E (pt) Compostos moduladores de receptores de esteroides e metodos
NO20010446L (no) Substituert anilidforbindelser og metoder
PT918774E (pt) Compostos moduladores do receptor para androgenio e metodos
BR9804437A (pt) Compostos para a osteoporose
BR9910180A (pt) Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
DK1054887T3 (da) Bicykliske pyridin- og pyrimidinderivater som neuropeptid Y-receptorantagonister
IL161829A (en) 1,2,4 - thiadiazole derivatives, some of which are novel and pharmaceutical compositions comprising the same for treating disorders mediated by melanocortin receptor modulators
BR9913255A (pt) Composto, composição farmacêutica, processo de tratamento de uma condição de doença mediada por metaloproteinase, processo para preparar um composto, e, uso de um composto
BR9713147A (pt) Benzamidoaldeìdo, uso do mesmo, benzamida, e, preparação medicamentosa para administração oral, parenteral ou intraperitoneal.
UY24949A1 (es) Compuestos calcilíticos
UY26130A1 (es) Compuestos para tratar la obesidad
BR0316070A (pt) Composto, composição farmacêutica, uso de um composto e, método para modular mchr
BRPI0418255A (pt) derivados de piperazina e piperidina n-substituìdos
BR0113590A (pt) 7-oxo-piridopirimidinas
BR0016952A (pt) Compostos derivados de fenil-piperazina substituìdos, composição farmacêutica, uso e método

Legal Events

Date Code Title Description
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA DA PETICAO NO 020050080910/RJ DE 11/08/2005, O PEDIDO DE TRANSFERENCIA REQUERIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.